0.9000 +0.05 (6.50%)
After hours: 5:08PM EDT
|Bid||0.8400 x 3100|
|Ask||0.8480 x 800|
|Day's Range||0.8200 - 0.8683|
|52 Week Range||0.6900 - 6.7400|
|Beta (3Y Monthly)||3.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.60|
Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Conatus Pharmaceuticals Inc. (CNAT) today announced a new publication1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats with advanced cirrhosis including increased portal pressure induced by chronic carbon tetrachloride administration. Portal pressure was significantly reduced in emricasan-treated rats relative to vehicle-treated control animals. Reduced portal pressure was associated with significantly better liver function, reduced liver inflammation, and reduced fibrosis.
Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conatus Pharmaceuticals Inc. (CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, was also selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor.
Biotech stocks ended higher for the second straight week, with the presentations at the American Association of Cancer Research annual meeting taking the spotlight. Additionally, there were clinical trial ...
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus Pharmaceuticals Inc. (CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct a series of scheduled meetings with investment professionals and present a company overview on Tuesday, April 9, 2019, from 10:30 a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50 a.m. EDT). Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need.
Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.
Shares of microcap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) are heading crashing following the release of results from a midstage trial of its non-alcoholic steatohepatitis candidate. What Happened ...
The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement with no worsening of steatohepatitis compared with placebo at week 72. “Although emricasan did not have the desired effect in these earlier-stage NASH fibrosis patients, we believe its demonstrated biomarker activity across a broad spectrum of liver disease warrants continued evaluation in more advanced-stage NASH cirrhosis patients,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus.
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) will detail results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader in the ENCORE-PH trial, will deliver the presentation on Saturday, April 13, at 4:00 p.m. CEST.
Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.
SAN DIEGO, March 08, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018, and.
Conatus Pharmaceuticals Inc. (CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2018, after the market close on Friday, March 8, 2019. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Friday, March 8, 2019, to discuss the financial results and provide a corporate update. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Steven Mento became the CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)Read More...
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
Conatus Pharmaceuticals Inc. (CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screening in the ENCORE-LF clinical trial complete, we remain on track for clinical events as announced last quarter, with top-line results expected in mid-2019,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development at Conatus. The ENCORE-LF clinical trial is designed to evaluate safety, dosing and efficacy of emricasan in patients with decompensated NASH cirrhosis as an integral part of the company’s initial registration strategy.
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.